Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RX001 in KRAS mutant advanced NSCLC
NCT06934590Phase 1Not yet recruiting
- Sponsor
- GeneCraft
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RX001 in non-small cell lung cancer (NSCLC), sponsored by GeneCraft. Primary endpoint: Incidence of treatment-related serious adverse event (SAE) rate at 12 weeks. Planned start May 2025; status: not yet recruiting.
02
Drugs
RX001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06934590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934590.